Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia

被引:0
|
作者
C Quiney
C Billard
A M Faussat
C Salanoubat
A Ensaf
Y Naït-Si
J D Fourneron
J-P Kolb
机构
[1] UMR 736 INSERM/Université Paris VI,
[2] Centre de Recherches Biomédicales des Cordeliers,undefined
[3] Laboratory of Galenic and Industrial Pharmacy,undefined
[4] Faculty of Pharmacy,undefined
来源
Leukemia | 2006年 / 20卷
关键词
hyperforin; B-CLL; apoptosis; nitric oxide; p27;
D O I
暂无
中图分类号
学科分类号
摘要
The effects of the hyperforin (HF), a natural phloroglucinol purified from Hypericum perforatum, were investigated ex vivo on leukemic cells from patients with B-cell chronic lymphocytic leukemia (B-CLL). HF was found to promote apoptosis of B-CLL cells, as shown by time- and dose-dependent stimulation of phosphatidylserine externalization and DNA fragmentation, by disruption of the mitochondrial transmembrane potential, caspase-3 activation and cleavage of the caspase substrate PARP-1. Moreover, HF-induced downregulation of Bcl-2 and Mcl-1, two antiapoptotic proteins that control mitochondrial permeability. HF also downregulated two proteins which are overexpressed by B-CLL patients' cells, the cell cycle inhibitor p27kip1 through caspase-dependent cleavage into a p23 form, and the nitric oxid (NO) synthase of type 2 (inducible NO synthase). This latter was accompanied by reduction in the production of NO known to be antiapoptotic in B-CLL cells. Preventing effects of the general caspase inhibitor z-VAD-fmk indicated that HF-promoted apoptosis of B-CLL cells was mostly caspase dependent. Furthermore, normal B lymphocytes purified from healthy donors appeared less sensitive to HF-induced apoptosis than B-CLL cells. These results indicate that HF may be of interest in the development of new therapies for B-CLL based on the induction of apoptosis and combination with cell cycle-dependent antitumor drugs.
引用
收藏
页码:491 / 497
页数:6
相关论文
共 50 条
  • [1] Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia
    Quiney, C
    Billard, C
    Faussat, AM
    Salanoubat, C
    Ensaf, A
    Naït-Si, Y
    Fourneron, J
    Kolb, JP
    LEUKEMIA, 2006, 20 (03) : 491 - 497
  • [2] Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
    Jensen, Markus
    Engert, Andreas
    Weissinger, Florian
    Knauf, Wolfgang
    Kimby, Eva
    Poynton, Christopher
    Oliff, Ira Anton
    Rummel, Mathias J.
    Oesterborg, Anders
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (02) : 139 - 149
  • [3] Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
    Markus Jensen
    Andreas Engert
    Florian Weissinger
    Wolfgang Knauf
    Eva Kimby
    Christopher Poynton
    Ira Anton Oliff
    Mathias J. Rummel
    Anders Österborg
    Investigational New Drugs, 2008, 26 : 139 - 149
  • [4] VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia
    Prezma, T.
    Shteinfer, A.
    Admoni, L.
    Raviv, Z.
    Sela, I.
    Levi, I.
    Shoshan-Barmatz, V.
    CELL DEATH & DISEASE, 2013, 4 : e809 - e809
  • [5] VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia
    T Prezma
    A Shteinfer
    L Admoni
    Z Raviv
    I Sela
    I Levi
    V Shoshan-Barmatz
    Cell Death & Disease, 2013, 4 : e809 - e809
  • [6] LEUKEMIC MENINGITIS IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA
    STEINBERG, JP
    PECORA, M
    LOKEY, JL
    CANCER TREATMENT REPORTS, 1985, 69 (06): : 687 - 688
  • [7] Leukemic meningitis in B-cell chronic lymphocytic leukemia (CLL).
    Caldera, H
    Raez, L
    Hidron, A
    Henao, A
    Goodman, M
    BLOOD, 1998, 92 (10) : 260B - 260B
  • [8] Molecular mechanisms of pro-apoptotic activity of alemtuzumab: Potential prognostic implications and the rationale for combined therapy in B-cell chronic lymphocytic leukemia patients.
    Smolewski, P
    Szmigielska-Kaplon, A
    Cebula, B
    Jamroziak, K
    Rogalinska, M
    Kilianska, Z
    Robak, T
    BLOOD, 2003, 102 (11) : 925A - 925A
  • [9] VDAC1-Based Peptides: Novel Pro-Apoptotic Agents and a Potential Therapeutic Drug for B-Cell Chronic Lymphocytic Leukemia
    Shoshan-Barmatz, Varda
    Prazma, Tal
    Shteinfer, Anna
    Admoni, Lee
    Sela, Ilan
    BIOPHYSICAL JOURNAL, 2013, 104 (02) : 659A - 660A
  • [10] A novel pro-apoptotic agent SDX-101 (R-etodolac) for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
    Jenson, M
    Engert, A
    Goebeler, ME
    Weissinger, F
    Wilhelm, M
    Österborg, A
    Knauf, W
    Kimby, EK
    Rosen, PJ
    Poynton, C
    Rummel, MJ
    Hillmen, P
    Oliff, I
    Kennedy, B
    Jullusson, G
    Latven, L
    Scranton, SA
    Paradiso, LJ
    BLOOD, 2003, 102 (11) : 674A - 674A